116.63
price down icon0.50%   -0.59
after-market After Hours: 116.65 0.02 +0.02%
loading
Novartis Ag Adr stock is traded at $116.63, with a volume of 1.42M. It is down -0.50% in the last 24 hours and down -3.62% over the past month. Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
See More
Previous Close:
$117.22
Open:
$117.18
24h Volume:
1.42M
Relative Volume:
0.85
Market Cap:
$246.37B
Revenue:
$55.19B
Net Income/Loss:
$13.65B
P/E Ratio:
17.00
EPS:
6.86
Net Cash Flow:
$16.81B
1W Performance:
-1.14%
1M Performance:
-3.62%
6M Performance:
+11.34%
1Y Performance:
+4.20%
1-Day Range:
Value
$116.30
$117.61
1-Week Range:
Value
$115.77
$118.11
52-Week Range:
Value
$96.06
$124.83

Novartis Ag Adr Stock (NVS) Company Profile

Name
Name
Novartis Ag Adr
Name
Phone
-
Name
Address
-
Name
Employee
75,883
Name
Twitter
@novartis
Name
Next Earnings Date
2025-07-17
Name
Latest SEC Filings
Name
NVS's Discussions on Twitter

Compare NVS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
116.63 226.92B 55.19B 13.65B 16.81B 6.86
Drug Manufacturers - General icon
LLY
Lilly Eli Co
760.08 684.93B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
167.26 404.87B 90.63B 22.66B 16.40B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
189.31 337.77B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
MRK
Merck Co Inc
81.75 207.49B 63.92B 17.43B 17.04B 6.87

Novartis Ag Adr Stock (NVS) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-13-25 Downgrade UBS Buy → Neutral
Feb-12-25 Initiated Morgan Stanley Underweight
Feb-04-25 Upgrade Deutsche Bank Hold → Buy
Dec-04-24 Downgrade HSBC Securities Hold → Reduce
Sep-11-24 Downgrade BofA Securities Buy → Neutral
Sep-05-24 Downgrade Goldman Buy → Neutral
Sep-03-24 Downgrade Jefferies Buy → Hold
Jul-19-24 Downgrade Deutsche Bank Buy → Hold
May-30-24 Initiated Goldman Buy
Feb-23-24 Initiated BMO Capital Markets Market Perform
Jan-23-24 Initiated Morgan Stanley Equal-Weight
Jan-16-24 Resumed UBS Buy
Dec-18-23 Downgrade HSBC Securities Buy → Hold
Sep-25-23 Upgrade Morgan Stanley Underweight → Equal-Weight
Jul-14-23 Initiated HSBC Securities Buy
Apr-26-23 Upgrade Deutsche Bank Hold → Buy
Mar-27-23 Upgrade Deutsche Bank Sell → Hold
Jan-26-23 Downgrade Citigroup Buy → Neutral
Dec-05-22 Upgrade Stifel Hold → Buy
Sep-15-22 Downgrade Credit Suisse Neutral → Underperform
Sep-14-22 Downgrade Berenberg Buy → Hold
May-09-22 Downgrade Wolfe Research Outperform → Peer Perform
Jan-10-22 Resumed Citigroup Buy
Dec-14-21 Downgrade Redburn Buy → Neutral
Dec-06-21 Downgrade Exane BNP Paribas Outperform → Neutral
Dec-03-21 Downgrade Bryan Garnier Buy → Neutral
Sep-20-21 Downgrade Deutsche Bank Hold → Sell
Mar-22-21 Initiated Bernstein Mkt Perform
Mar-10-21 Downgrade Argus Buy → Hold
Feb-01-21 Downgrade Cowen Outperform → Market Perform
Jan-15-21 Initiated Deutsche Bank Buy
Sep-29-20 Initiated Berenberg Buy
Sep-10-20 Upgrade UBS Neutral → Buy
Sep-01-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-15-20 Upgrade Citigroup Neutral → Buy
Mar-10-20 Upgrade Morgan Stanley Underweight → Equal-Weight
Feb-25-20 Downgrade Guggenheim Buy → Neutral
Apr-25-19 Upgrade Guggenheim Neutral → Buy
Apr-25-19 Upgrade Liberum Hold → Buy
Apr-10-19 Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-02-19 Downgrade JP Morgan Neutral → Underweight
Dec-11-18 Resumed Jefferies Buy
Oct-09-18 Initiated Guggenheim Neutral
Sep-10-18 Upgrade BofA/Merrill Underperform → Buy
May-29-18 Downgrade HSBC Securities Buy → Hold
May-25-18 Upgrade Credit Suisse Underperform → Neutral
Jan-25-18 Reiterated Leerink Partners Outperform
Dec-06-17 Downgrade BofA/Merrill Neutral → Underperform
Jul-26-17 Upgrade Morgan Stanley Underweight → Overweight
Jul-05-17 Downgrade Credit Suisse Neutral → Underperform
Mar-09-17 Initiated Liberum Buy
View All

Novartis Ag Adr Stock (NVS) Latest News

pulisher
Jul 29, 2025

Hematologist Dissatisfaction with Current Warm Autoimmune Hemolytic Anemia (w-AIHA) Treatment Spurs Interest in Late-Stage Pipeline, According to Spherix Global Insights - GlobeNewswire Inc.

Jul 29, 2025
pulisher
Jul 25, 2025

NVS’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com

Jul 25, 2025
pulisher
Jul 17, 2025

Novartis Holds a Strong Branded Drug Portfolio, Supporting Steady Long-Term Growth - Morningstar

Jul 17, 2025
pulisher
Jul 17, 2025

Novartis Beats On Q2 Earnings And Sales, CFO Retires, Stock Down - Barchart.com

Jul 17, 2025
pulisher
Jul 17, 2025

Novartis ADR earnings beat by $0.07, revenue topped estimates - Investing.com Nigeria

Jul 17, 2025
pulisher
Jul 15, 2025

Will Key Drugs Maintain Momentum For Novartis In Q2 Earnings? - Barchart.com

Jul 15, 2025
pulisher
Jul 10, 2025

Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx® for hidradenitis suppurativa (HS) - Barchart.com

Jul 10, 2025
pulisher
Jul 03, 2025

Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study - TradingView

Jul 03, 2025
pulisher
Jul 01, 2025

Incyte Gains 9.2% In Three Months: Buy, Hold Or Sell The Stock? - Barchart.com

Jul 01, 2025
pulisher
Jun 16, 2025

5 Large Drug Stocks That Are Poised To Ride On Sector Recovery - Barchart.com

Jun 16, 2025
pulisher
Jun 11, 2025

NVO Stock Gains After Parvus Asset Management Builds Stake - Barchart.com

Jun 11, 2025
pulisher
Jun 10, 2025

The Novartis Oncology Young Canadian Investigator Awards (NOYCIA) returns for its 22nd year at ASCO 2025 - Barchart.com

Jun 10, 2025
pulisher
Jun 03, 2025

Bristol Myers Collaborates With BNTX For Oncology Candidate - Barchart.com

Jun 03, 2025
pulisher
May 29, 2025

Penicillin Market Research Report 2025 - GlobeNewswire Inc.

May 29, 2025
pulisher
May 28, 2025

Why Value Investing Has Worked Better Outside the US - Morningstar

May 28, 2025
pulisher
May 22, 2025

Regeneron Initial Data On Multiple Myeloma Drug Encouraging - Barchart.com

May 22, 2025
pulisher
May 19, 2025

Bybit Gold & FX now supports stock trading: Explore new markets! - Bybit Announcement

May 19, 2025
pulisher
May 15, 2025

GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug - Yahoo Finance

May 15, 2025
pulisher
May 14, 2025

Novartis Canada extends Health Equity Initiative effort, fueling innovation and impact for second year - Barchart.com

May 14, 2025
pulisher
May 02, 2025

NVS’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com

May 02, 2025
pulisher
Apr 29, 2025

Novartis Earnings: Strong First-Quarter Supports Increased Full-Year Guidance - Morningstar

Apr 29, 2025
pulisher
Apr 29, 2025

Novartis ADR earnings beat by $0.20, revenue topped estimates - Investing.com

Apr 29, 2025
pulisher
Apr 29, 2025

Novartis Holds a Strong Branded Drug Portfolio Supporting Steady Long-Term Growth - Morningstar

Apr 29, 2025
pulisher
Apr 29, 2025

Novartis Beats On Q1 Earnings And Sales, Raises Guidance, Stock Up - Barchart.com

Apr 29, 2025
pulisher
Apr 22, 2025

Roche to invest US$50-billion in U.S. to avoid Trump tariffs, create 12,000 jobs - The Globe and Mail

Apr 22, 2025
pulisher
Apr 21, 2025

Novartis to Report Q1 Earnings: Will Key Drugs Maintain Momentum? - Yahoo Finance

Apr 21, 2025
pulisher
Apr 11, 2025

Swiss pharmaceutical giant announces plans for $1.1B campus in San Diego - fox5sandiego.com

Apr 11, 2025

Novartis Ag Adr Stock (NVS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general MRK
$81.75
price down icon 1.06%
drug_manufacturers_general NVO
$50.03
price down icon 7.25%
$301.37
price down icon 0.72%
$189.31
price down icon 1.00%
$114.76
price up icon 0.46%
Cap:     |  Volume (24h):